Insider · CIK 0001644079
John Glasspool
Files at RLMD (RELMADA THERAPEUTICS, INC.). First filing -, latest -.
In brief
John Glasspool files SEC Form 4 as director at RLMD (RELMADA THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Glasspool has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Appreciation Rightsderivative | +164,000 | $0.00 | $0 | 164,000 | Dec 16, 2025 |
| Jun 26, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 30, 2025 |
| Dec 15, 2023 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +31,522 | $0.00 | $0 | 31,522 | Dec 19, 2023 |
Questions about John Glasspool
Answered from the filings on this page, as of the latest one.
Is John Glasspool buying or selling?
John Glasspool has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Glasspool's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Glasspool has 0.
Where does John Glasspool file Form 4?
John Glasspool has filed Form 4 at RLMD (RELMADA THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.